Oncology

The rising prevalence of urologic cancers, along with the increased use of hormone therapies and the approval of novel biologics, is driving strong growth in the urologic cancer market globally through 2022.

The FDA has asked Juno Therapeutics to halt the phase 2 clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, the ROCKET trial.

Panelists at the policy summit hosted by National Comprehensive Cancer Network agreed that sharing information can help create a learning system that can improve patient outcomes.

Michael Kolodziej, MD, national medical director for oncology strategy at Aetna, said that the evaluation of academic medical centers has allowed the company to examine what lies at the heart of creating optimal patient outcomes and experiences.

The American Society of Clinical Oncology (ASCO) has published a paper that shares the various innovative approaches developed by the society for guideline development and implementation.

A federal appeals court has overturned a previous ruling and decided that biosimilar manufacturers must provide the innovator company a 180-day notice only after receiving FDA-approval for its biosimilar product.

The approval was based on the results of the phase 3 ENDEAVOR study.

Researchers from the Duke Cancer Institute have discovered that mutations in the BRCA1 gene can dramatically increase the probability of a woman developing serous or serous-like endometrial carcinoma.

Gregory C. Simon, executive director, White House Cancer Task Force, spoke at the National Comprehensive Cancer Network Policy Summit, held just 2 days before the Cancer Moonshot Summit.

Retail prices for 23 cancer drugs may be highest in the United States, but are less affordable in low-income countries despite lower retail prices.

The Oncology Care Model is one of the most recent bundled payment programs announced by CMS, going into effect July 1. Participants will need a robust data analytics program in order to meet practice requirements, and achieve clinical and financial goals. Read on for tips to achieve data-driven success, and a simulation of what practice data will look like under the model.

At the Cancer Moonshot Summit, Vice President Joe Biden cautioned research scientists to expect funding cuts if they failed to report, in a timely manner, the findings of clinical trials.

CMS has announced that the Oncology Care Model (OCM) developed by the Center for Medicare and Medicaid Innovation has 196 practices and 17 payers enrolled for participation.

Jennifer Malin, MD, staff vice president, Clinical Strategy, Anthem, said that while there are a lot of quality measures being developed by several organizations, care gaps persist.

When comparing a private practice with a larger healthcare system, Linda Bosserman, MD, assistant clinical professor and staff physician, City of Hope, said that the challenges can run across the system.

Jennifer Malin, MD, staff vice president, Clinical Strategy, Anthem, spoke about her health plan’s requirements on quality measures and whether they resonate what CMS requires providers to submit.